Key result
Percutaneous left atrial appendage exclusion is a feasible, safe, and practical therapy that may eliminate the need for anticoagulation and reduce cardioembolic events in atrial fibrillation.
Why the study?
Is percutaneous left atrial appendage exclusion a feasible and safe alternative to anticoagulation for preventing cardioembolic events in patients with atrial fibrillation?
Is percutaneous left atrial appendage exclusion a feasible and safe alternative to anticoagulation for preventing cardioembolic events in patients with atrial fibrillation?
This review highlights the anatomic and functional importance of the LAA and supports percutaneous LAA exclusion as a feasible and safe strategy for stroke prevention in atrial fibrillation.
Supports LAA exclusion in select AF patients intolerant to anticoagulation; leaves open efficacy confirmation in randomized trials.
The left atrial appendage (LAA) is a cardiac structure with unique anatomic and functional features. It is significantly more than a simple chamber appended to the left atrium (LA), differing from the LA in structure, function, and hormonal activity. Unfortunately, it is the source of more than 90% of cardiac-based emboli, particularly in atrial fibrillation, mandating lifelong anticoagulation. Percutaneous LAA exclusion was developed to limit or eliminate cardioembolic events in patients with atrial fibrillation. Benign healing of the appendage occurs without adverse hemodynamic effects, and with no residual surface thrombus or tissue damage. The feasibility of this treatment is now established, suggesting that percutaneous therapy is safe, practical and possibly effective to eliminate the need for anticoagulation and significantly reduce cardioembolic events.
No takes yet. Share an insight, caveat, or question.
Hara et al. (2009) conducted a review in Atrial fibrillation. Percutaneous left atrial appendage exclusion was evaluated. Percutaneous left atrial appendage exclusion is a feasible, safe, and practical therapy that may eliminate the need for anticoagulation and reduce cardioembolic events in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: